Élisabeth Brambilla
A5023993622- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- RNA modifications and cancer
- Neuroendocrine Tumor Research Advances
- Lung Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Cancer-related gene regulation
- Medical Imaging and Pathology Studies
- Neuroblastoma Research and Treatments
- Telomeres, Telomerase, and Senescence
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Metastasis and carcinoma case studies
- Radiomics and Machine Learning in Medical Imaging
- MicroRNA in disease regulation
- Cancer Research and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Ubiquitin and proteasome pathways
- Ferroptosis and cancer prognosis
- DNA Repair Mechanisms
- Colorectal Cancer Treatments and Studies
Université Grenoble Alpes
2014-2025
Inserm
2014-2025
Centre National de la Recherche Scientifique
1993-2025
Centre Hospitalier Universitaire de Grenoble
2012-2023
Institut pour l'avancée des biosciences
2010-2023
Université Joseph Fourier
2008-2023
Institut de Biosciences et Biotechnologies
2019-2023
Hôpital Albert Michallon
2009-2021
University of Missouri–Kansas City
2018
Université Paris-Saclay
2016-2018
Adjuvant cisplatin-based chemotherapy improves survival among patients with completely resected non-small-cell lung cancer, but there is no validated clinical or biologic predictor of the benefit chemotherapy.We used immunohistochemical analysis to determine expression excision repair cross-complementation group 1 (ERCC1) protein in operative specimens cancer. The had been enrolled International Lung Cancer Trial, thereby allowing a comparison effect adjuvant on survival, according ERCC1...
The classification of neuroendocrine neoplasms (NENs) differs between organ systems and currently causes considerable confusion. A uniform framework for NENs at any anatomical location may reduce inconsistencies contradictions among the various in use. suggested here is intended to allow pathologists clinicians manage their patients with consistently, while acknowledging organ-specific differences criteria, tumor biology, prognostic factors. based on a consensus conference held International...
FGFR1 amplification provides a therapeutic target for squamous cell lung cancer, which is resistant to other targeted cancer drugs.
Large-scale detection of ectopic gene activations reveals a source potential cancer biomarkers and correlates with aggressive metastasis-prone lung tumors.
While genomically targeted therapies have improved outcomes for patients with lung adenocarcinoma, little is known about the genomic alterations which drive squamous cell cancer. Sanger sequencing of tyrosine kinome identified mutations in DDR2 kinase gene 3.8% cancers and lines. Squamous cancer lines harboring were selectively killed by knock-down RNAi or treatment multi-targeted inhibitor dasatinib. Tumors established from a mutant line sensitive to dasatinib xenograft models. Expression...
The pattern of mutations in human lung cancer differs by tumor subtype and is a useful addition to histology for selecting targeted therapy improving patient survival.
The new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification provides, first time, standardized terminology cancer diagnosis in small biopsies and cytology; this was not primarily addressed by previous World Health Organization classifications. Until recently there have been no therapeutic implications to further NSCLC, so little attention has given distinction squamous cell carcinoma tissue samples....
We collected 75 primary pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements to better define their clinical, histologic, and immunohistochemical profile. The patient's age ranged from 42 81 years (mean 65 years), the male-to-female ratio was 9.7:1. Sixty-nine patients (92%) were smokers. Cough hemoptysis most frequent presenting symptoms. Fifty-nine (65%) died of disease: only stage significantly predicts overall survival (p = 0.0273). Microscopically, based on WHO...
The excision repair cross-complementation group 1 (ERCC1) protein is a potential prognostic biomarker of the efficacy cisplatin-based chemotherapy in non–small-cell lung cancer (NSCLC). Although several ongoing trials are evaluating level expression ERCC1, no consensus has been reached regarding method for evaluation.
Tumor lymphocytic infiltration (TLI) has differing prognostic value among various cancers. The objective of this study was to assess the effect TLI in lung cancer.A discovery set (one trial, n = 824) and a validation (three trials, 984) that evaluated benefit platinum-based adjuvant chemotherapy non-small-cell cancer were used as part LACE-Bio (Lung Adjuvant Cisplatin Evaluation Biomarker) study. defined intense versus nonintense. main end point overall survival (OS); secondary points...
Pulmonary large-cell neuroendocrine carcinomas (LCNECs) have similarities with other lung cancers, but their precise relationship has remained unclear. Here we perform a comprehensive genomic (n = 60) and transcriptomic 69) analysis of 75 LCNECs identify two molecular subgroups: "type I LCNECs" bi-allelic TP53 STK11/KEAP1 alterations (37%), II enriched for inactivation RB1 (42%). Despite sharing adenocarcinomas squamous cell carcinomas, no transcriptional was found; instead form distinct...
Squamous cell carcinoma (SCC) of the lung is a frequent and aggressive cancer type. Gene amplifications, known activating mechanism oncogenes, target 3q26-qter region as one most frequently gained/amplified genomic sites in SCC various types. Here, we used array comparative hybridization to delineate consensus 3q26.3 amplifications SCC. Recurrent occur 20% (136 tumors total) map core 2 Mb (Megabases) that encompasses SOX2, transcription factor gene. Intense SOX2 immunostaining nuclei SCC,...